AIGH Capital Management LLC trimmed its stake in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 18.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,026,569 shares of the company's stock after selling 698,635 shares during the quarter. Theratechnologies accounts for 1.7% of AIGH Capital Management LLC's portfolio, making the stock its 21st largest holding. AIGH Capital Management LLC owned approximately 6.58% of Theratechnologies worth $5,478,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Harbour Investments Inc. grew its position in Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock valued at $159,000 after acquiring an additional 14,655 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Theratechnologies in the 4th quarter worth about $27,000. JPMorgan Chase & Co. acquired a new stake in shares of Theratechnologies during the 4th quarter worth about $33,000. Wealthspire Advisors LLC lifted its holdings in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock valued at $129,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Theratechnologies during the 4th quarter valued at about $40,000.
Analyst Upgrades and Downgrades
Separately, Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.
View Our Latest Research Report on Theratechnologies
Theratechnologies Stock Up 1.0 %
THTX stock traded up $0.02 during midday trading on Thursday, reaching $1.49. 149,604 shares of the company's stock traded hands, compared to its average volume of 292,613. The company has a 50-day simple moving average of $1.62 and a two-hundred day simple moving average of $1.50. Theratechnologies Inc. has a 1-year low of $1.08 and a 1-year high of $2.18. The company has a market cap of $68.28 million, a price-to-earnings ratio of -14.85 and a beta of 1.11.
About Theratechnologies
(
Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
